Impact of bariatric surgery on the development of diabetic microvascular and macrovascular complications.

Bariatric surgery Diabetes mellitus 2 Diabetic macrovascular complications Diabetic microvascular complications Roux-en-Y gastric bypass

Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
07 2021
Historique:
received: 07 05 2020
accepted: 24 07 2020
pubmed: 5 8 2020
medline: 30 9 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

While bariatric surgery has been shown to improve type 2 diabetes (DM) control in the obese population, the effect on long-term DM complications has been less thoroughly investigated. The purpose of this study was to assess the development of microvascular and macrovascular complications in obese DM patients undergoing bariatric surgery. New York patients' records from the SPARCS database in years 2006-2012 were used to identify obese patients with DM. Patients undergoing bariatric surgery were compared with patients managed medically, matched for age and gender. Patients were grouped based on baseline presence of controlled or uncontrolled DM and followed over time for the development of micro- and macrovascular complications. Cumulative incidence of complications was estimated with death treated as a competing risk event. Multivariable proportional sub-distribution hazards models were used to compare the risk of complications among different patient groups after adjusting for possible confounding factors. A total of 88,981 patients were reviewed, including 15,585 (18%) that were treated with bariatric surgery. Surgery patients had significantly lower risk of microvascular complications compared to non-surgery patients (controlled diabetes: HR = 0.40, 95% CI 0.37-0.42; uncontrolled diabetes: HR = 0.51, 95% CI 0.37-0.71). Similarly, the surgical patients were noted to have a significantly lower risk for macrovascular complications compared to non-surgery patients (controlled diabetes: HR = 0.43, 95% CI 0.40-0.46; uncontrolled diabetes: HR = 0.44, 95% CI 0.28-0.69). Cumulative incidence of microvascular complications was lower at 1, 5 and 9 years for the surgical groups for controlled and uncontrolled DM. Similar trends were observed for the macrovascular complications. Bariatric surgery appears to prevent complications of DM. Bariatric surgery patients with DM experienced significantly lower rates of microvascular and macrovascular complications, compared to non-surgically treated comparison group. Bariatric surgery was noted to offer protective benefits for both complicated and non-complicated DM patients. This reduced rate of complications was sustained in the long term.

Sections du résumé

BACKGROUND
While bariatric surgery has been shown to improve type 2 diabetes (DM) control in the obese population, the effect on long-term DM complications has been less thoroughly investigated. The purpose of this study was to assess the development of microvascular and macrovascular complications in obese DM patients undergoing bariatric surgery.
METHODS
New York patients' records from the SPARCS database in years 2006-2012 were used to identify obese patients with DM. Patients undergoing bariatric surgery were compared with patients managed medically, matched for age and gender. Patients were grouped based on baseline presence of controlled or uncontrolled DM and followed over time for the development of micro- and macrovascular complications. Cumulative incidence of complications was estimated with death treated as a competing risk event. Multivariable proportional sub-distribution hazards models were used to compare the risk of complications among different patient groups after adjusting for possible confounding factors.
RESULTS
A total of 88,981 patients were reviewed, including 15,585 (18%) that were treated with bariatric surgery. Surgery patients had significantly lower risk of microvascular complications compared to non-surgery patients (controlled diabetes: HR = 0.40, 95% CI 0.37-0.42; uncontrolled diabetes: HR = 0.51, 95% CI 0.37-0.71). Similarly, the surgical patients were noted to have a significantly lower risk for macrovascular complications compared to non-surgery patients (controlled diabetes: HR = 0.43, 95% CI 0.40-0.46; uncontrolled diabetes: HR = 0.44, 95% CI 0.28-0.69). Cumulative incidence of microvascular complications was lower at 1, 5 and 9 years for the surgical groups for controlled and uncontrolled DM. Similar trends were observed for the macrovascular complications.
CONCLUSIONS
Bariatric surgery appears to prevent complications of DM. Bariatric surgery patients with DM experienced significantly lower rates of microvascular and macrovascular complications, compared to non-surgically treated comparison group. Bariatric surgery was noted to offer protective benefits for both complicated and non-complicated DM patients. This reduced rate of complications was sustained in the long term.

Identifiants

pubmed: 32748271
doi: 10.1007/s00464-020-07848-2
pii: 10.1007/s00464-020-07848-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3923-3931

Références

Wild S et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053
doi: 10.2337/diacare.27.5.1047
Hofso D et al (2019) Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial. Lancet Diabetes Endocrinol 7(12):912–924
doi: 10.1016/S2213-8587(19)30344-4
Grams J, Garvey WT (2015) Weight loss and the prevention and treatment of type 2 diabetes using lifestyle therapy, pharmacotherapy, and bariatric surgery: mechanisms of action. Curr Obes Rep 4(2):287–302
doi: 10.1007/s13679-015-0155-x
Dyck PJ et al (1993) The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 43(4):817–824
doi: 10.1212/WNL.43.4.817
Adams TD et al (2016) Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care 39(6):912–923
doi: 10.2337/dc16-0157
Sjostrom L et al (2014) Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311(22):2297–2304
doi: 10.1001/jama.2014.5988
Yip S, Plank LD, Murphy R (2013) Gastric bypass and sleeve gastrectomy for type 2 diabetes: a systematic review and meta-analysis of outcomes. Obes Surg 23(12):1994–2003
doi: 10.1007/s11695-013-1030-z
Ricci C et al (2015) Long-term effects of bariatric surgery on type II diabetes, hypertension and hyperlipidemia: a meta-analysis and meta-regression study with 5-year follow-up. Obes Surg 25(3):397–405
doi: 10.1007/s11695-014-1442-4
Wu GZ et al (2016) Meta-analysis of bariatric surgery versus non-surgical treatment for type 2 diabetes mellitus. Oncotarget 7(52):87511–87522
doi: 10.18632/oncotarget.11961
Coleman KJ et al (2016) Long-term microvascular disease outcomes in patients with type 2 diabetes after bariatric surgery: evidence for the legacy effect of surgery. Diabetes Care 39(8):1400–1407
doi: 10.2337/dc16-0194
Sheng B et al (2017) The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis. Obes Surg 27(10):2724–2732
doi: 10.1007/s11695-017-2866-4
Aminian A et al (2019) Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA 322(13):1271–1282
doi: 10.1001/jama.2019.14231
Tandon N, Ali MK, Narayan KM (2012) Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Am J Cardiovasc Drugs 12(1):7–22
doi: 10.2165/11594650-000000000-00000
Mingrone G et al (2015) Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 386(9997):964–973
doi: 10.1016/S0140-6736(15)00075-6
Schauer PR et al (2017) Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med 376(7):641–651
doi: 10.1056/NEJMoa1600869
Romeo S et al (2012) Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care 35(12):2613–2617
doi: 10.2337/dc12-0193
Chen Y et al (2016) Gastric bypass surgery leads to long-term remission or improvement of type 2 diabetes and significant decrease of microvascular and macrovascular complications. Ann Surg 263(6):1138–1142
doi: 10.1097/SLA.0000000000001509
Miras AD et al (2019) Metabolic changes and diabetes microvascular complications 5 years after obesity surgery. Obes Surg 29(12):3907–3911
doi: 10.1007/s11695-019-04095-w
Kristensson FM et al (2020) Effects of Bariatric Surgery in Early- and Adult-Onset Obesity in the Prospective Controlled Swedish Obese Subjects Study. Diabetes Care 43(4):860–866
doi: 10.2337/dc19-1909
Carlsson LMS et al (2017) Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol 5(4):271–279
doi: 10.1016/S2213-8587(17)30061-X

Auteurs

Iliya Goldberg (I)

Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Health Sciences Center T18-040, Stony Brook University Medical Center, 100 Nichols Road, HSC T19, Stony Brook, NY, 11794, USA. iliya.goldberg@stonybrookmedicine.edu.

Lizhou Nie (L)

Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, 11794, USA.

Jie Yang (J)

Department of Family, Population and Preventive Medicine, Stony Brook University Medical Center, Stony Brook, NY, 11794, USA.

Salvatore Docimo (S)

Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T19, Stony Brook, NY, 11794, USA.

Silvana Obici (S)

Department of Endocrinology and Metabolism, Department of Medicine, Stony Brook University Medical Center, 100 Nichols Road, Stony Brook, NY, 11794, USA.

Mark Talamini (M)

Department of Surgery, Health Sciences Center T19-010, Stony Brook Medicine, Stony Brook, NY, 11794, USA.

Aurora Pryor (A)

Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T19, Stony Brook, NY, 11794, USA.

Konstantinos Spaniolas (K)

Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, 100 Nichols Road, HSC T19, Stony Brook, NY, 11794, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH